Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action-Reference-Cited by-同舟云学术

Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action

Published:2022-08 Issue: Volume:182 Page:106357
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Yang Jing,Wang Lingling,Guan Xiaoqing,Qin Jiang-Jiang

Publisher

Elsevier BV

Subject

Pharmacology

Reference148 articles.

1. Targeting STAT3 with silibinin to improve cancer therapeutics;Bosch-Barrera;Cancer Treat. Rev.,2017

2. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review;Qin;J. Exp. Clin. Cancer Res,2019

3. Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains;Shih;Life Sci.,2020

4. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy;Garg;Med. Res. Rev.,2020

5. Targeting oncogenic transcription factors by polyphenols: a novel approach for cancer therapy;Rajagopal;Pharm. Res.,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modification of a natural diterpene and its antitumor mechanism: Promoting apoptosis, suppressing migration, and inhibiting angiogenesis;Arabian Journal of Chemistry;2024-03

2. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

3. Bioactivities and Mechanisms of Action of Sinomenine and Its Derivatives: A Comprehensive Review;Molecules;2024-01-22

4. Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy;International Journal of Molecular Sciences;2024-01-13

5. Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers Matter;Cancers;2023-11-29